** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with "buy" rating and $20 PT, a 251.5% upside to the stock's last close
** Says co's Alzheimer's disease drug Zunveyl, which is a "next-generation symptomatic therapy" has been shown to have a "very low rate of GI side effects (only 1-2%)" compared to 30-40% with existing cholinesterase inhibitors, and "eliminate sleep disturbances"
** Says co has a "finely tuned sales force" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl
** Co has a "considerable long-term promise" that is not reflected in its current stock price, which has been "range-bound" due to its relatively unknown status among US investors - brokerage
** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s
** Stock fell ~53% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.